000266788 001__ 266788
000266788 005__ 20240118114610.0
000266788 0247_ $$2doi$$a10.1007/s00702-023-02709-3
000266788 0247_ $$2pmid$$apmid:37851107
000266788 0247_ $$2ISSN$$a0375-9245
000266788 0247_ $$2ISSN$$a0022-3026
000266788 0247_ $$2ISSN$$a0300-9564
000266788 0247_ $$2ISSN$$a1435-1463
000266788 037__ $$aDZNE-2024-00046
000266788 041__ $$aEnglish
000266788 082__ $$a610
000266788 1001_ $$00000-0002-9645-0553$$aVallucci, Maeva$$b0
000266788 245__ $$aThe specific NQO2 inhibitor, S29434, only marginally improves the survival of dopamine neurons in MPTP-intoxicated mice.
000266788 260__ $$aWien [u.a.]$$bSpringer$$c2024
000266788 3367_ $$2DRIVER$$aarticle
000266788 3367_ $$2DataCite$$aOutput Types/Journal article
000266788 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1705503157_18420
000266788 3367_ $$2BibTeX$$aARTICLE
000266788 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000266788 3367_ $$00$$2EndNote$$aJournal Article
000266788 520__ $$aOver the years, evidence has accumulated on a possible contributive role of the cytosolic quinone reductase NQO2 in models of dopamine neuron degeneration induced by parkinsonian toxin, but most of the data have been obtained in vitro. For this reason, we asked the question whether NQO2 is involved in the in vivo toxicity of MPTP, a neurotoxin classically used to model Parkinson disease-induced neurodegeneration. First, we show that NQO2 is expressed in mouse substantia nigra dopaminergic cell bodies and in human dopaminergic SH-SY5Y cells as well. A highly specific NQO2 inhibitor, S29434, was able to reduce MPTP-induced cell death in a co-culture system of SH-SY5Y cells with astrocytoma U373 cells but was inactive in SH-SY5Y monocultures. We found that S29434 only marginally prevents substantia nigra tyrosine hydroxylase+ cell loss after MPTP intoxication in vivo. The compound produced a slight increase of dopaminergic cell survival at day 7 and 21 following MPTP treatment, especially with 1.5 and 3 mg/kg dosage regimen. The rescue effect did not reach statistical significance (except for one experiment at day 7) and tended to decrease with the 4.5 mg/kg dose, at the latest time point. Despite the lack of robust protective activity of the inhibitor of NQO2 in the mouse MPTP model, we cannot rule out a possible role of the enzyme in parkinsonian degeneration, particularly because it is substantially expressed in dopaminergic neurons.
000266788 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000266788 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000266788 650_7 $$2Other$$aMPTP
000266788 650_7 $$2Other$$aNQO2
000266788 650_7 $$2Other$$aNeuroprotection
000266788 650_7 $$2Other$$aParkinson disease
000266788 650_7 $$2Other$$aS29434
000266788 650_7 $$0EC 1.6.99.-$$2NLM Chemicals$$aNRH - quinone oxidoreductase2
000266788 650_7 $$2NLM Chemicals$$aN-(2-(2-methoxy-6H-dipyrido(2,3-a-3,2-e)pyrrolizin-11-yl)ethyl)-2-furamide
000266788 650_7 $$0VTD58H1Z2X$$2NLM Chemicals$$aDopamine
000266788 650_2 $$2MeSH$$aMice
000266788 650_2 $$2MeSH$$aHumans
000266788 650_2 $$2MeSH$$aAnimals
000266788 650_2 $$2MeSH$$aDopaminergic Neurons: metabolism
000266788 650_2 $$2MeSH$$aMPTP Poisoning
000266788 650_2 $$2MeSH$$aNeuroblastoma
000266788 650_2 $$2MeSH$$aSubstantia Nigra: metabolism
000266788 650_2 $$2MeSH$$aDopamine: metabolism
000266788 650_2 $$2MeSH$$aMice, Inbred C57BL
000266788 650_2 $$2MeSH$$aDisease Models, Animal
000266788 7001_ $$00000-0003-0068-7204$$aBoutin, Jean A$$b1
000266788 7001_ $$00000-0002-6787-7291$$aJanda, Elzbieta$$b2
000266788 7001_ $$aBlandel, Florence$$b3
000266788 7001_ $$0P:(DE-2719)2810507$$aMusgrove, Ruth$$b4
000266788 7001_ $$0P:(DE-2719)2481741$$aDi Monte, Donato$$b5
000266788 7001_ $$00000-0003-0689-7923$$aFerry, Gilles$$b6
000266788 7001_ $$00000-0001-5607-3119$$aMichel, Patrick P$$b7
000266788 7001_ $$00000-0003-4823-276X$$aHirsch, Etienne C$$b8
000266788 773__ $$0PERI:(DE-600)1481655-6$$a10.1007/s00702-023-02709-3$$gVol. 131, no. 1, p. 1 - 11$$n1$$p1 - 11$$tJournal of neural transmission$$v131$$x0375-9245$$y2024
000266788 8564_ $$uhttps://pub.dzne.de/record/266788/files/DZNE-2024-00046_Restricted.pdf
000266788 8564_ $$uhttps://pub.dzne.de/record/266788/files/DZNE-2024-00046_Restricted.pdf?subformat=pdfa$$xpdfa
000266788 909CO $$ooai:pub.dzne.de:266788$$pVDB
000266788 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810507$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000266788 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2481741$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000266788 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000266788 9141_ $$y2024
000266788 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2023-10-21$$wger
000266788 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2023-10-21$$wger
000266788 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000266788 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000266788 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000266788 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000266788 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
000266788 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000266788 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000266788 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-21
000266788 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
000266788 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEURAL TRANSM : 2022$$d2023-10-21
000266788 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-21
000266788 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-21
000266788 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-21
000266788 9201_ $$0I:(DE-2719)1013008$$kAG Di Monte$$lNeurodegeneration and Neuroprotection in Parkinson´s Disease$$x0
000266788 980__ $$ajournal
000266788 980__ $$aVDB
000266788 980__ $$aI:(DE-2719)1013008
000266788 980__ $$aUNRESTRICTED